DAN: This article is about 30 important people who are working on making special medicines called psychedelics, which can help with mental health problems. These people come from different countries and work in different companies. They want to make these medicines available for everyone who needs them. Read from source...

1. The article is overly optimistic and hype-driven, ignoring the potential risks and challenges of psychedelic therapy, such as adverse effects, legal barriers, ethical concerns, and lack of scientific evidence.
2. The article focuses mostly on North American companies and influencers, neglecting the contributions and diversity of other regions and cultures that have a long history and tradition of using psychedelics for healing purposes.
3. The article does not provide any clear criteria or methodology for selecting the 30 executives, scientists, and influencers, making the list subjective and arbitrary. It also excludes other notable figures who are doing important work in the field.
4. The article uses vague and superficial descriptions of each person, without providing any concrete examples or achievements that demonstrate their impact and influence on the psychedelics industry and society.
5. The article repeats some of the same information and quotes from different sources, showing a lack of originality and creativity in research and writing. It also copies some of the content from other articles without proper attribution or citation.

Based on the article you provided, I have identified several psychedelics executives, scientists, and influencers that are worth watching in 2024 and beyond. They are:

- Janet Qi, CEO of PurMinds Neuropharma, a company focused on developing new treatments for neurological conditions using psychedelic compounds.
- George Scorsis, Executive Chairman of Red Light Holland, a company that cultivates and sells magical truffles containing psilocybin in the Netherlands.
- Rob McDowell, Founder and CEO of Field Trip Health, a company that operates clinics offering psychedelic-assisted therapies for various mental health conditions.
- James Konson, Chief Scientific Officer of MindMed, a company that develops psychedelic drugs for treatment-resistant depression and other indications.
- Cybin Corp., a biopharmaceutical company that focuses on developing psilocybin-based therapeutics for depression, anxiety, addiction, and other disorders.